Sagimet Biosciences, Inc. Class A (SGMT) Stock Forecast & Price Target

Compare

1,624 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SGMT Analyst Ratings

Strong Buy

8 Buy

0 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Sagimet

Biosciences, Inc. Class A

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SGMT Stock 12 Month Forecast

Average Price Target

$28.57

▲(351.34% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Sagimet Biosciences, Inc. Class A in the last 3 months. The average price target is $28.57 with a high forecast of $35.00 and a low forecast of $25.00. The average price target represents a 351.34% change from the last price of $6.33.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","36":"$36","9.75":"$9.75","18.5":"$18.5","27.25":"$27.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28.57,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$28.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,9.75,18.5,27.25,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.52,10.556923076923077,12.593846153846155,14.63076923076923,16.667692307692306,18.704615384615387,20.74153846153846,22.77846153846154,24.815384615384616,26.852307692307694,28.88923076923077,30.92615384615385,32.963076923076926,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.52,10.062307692307693,11.604615384615384,13.146923076923077,14.689230769230768,16.231538461538463,17.773846153846154,19.316153846153846,20.85846153846154,22.40076923076923,23.943076923076923,25.485384615384614,27.02769230769231,{"y":28.57,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.52,9.787692307692307,11.055384615384614,12.323076923076922,13.59076923076923,14.858461538461537,16.126153846153848,17.393846153846155,18.661538461538463,19.92923076923077,21.196923076923078,22.464615384615385,23.732307692307693,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.33,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.36,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.5,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.4,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.72,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.58,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.93,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.49,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.03,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.25,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.36,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.98,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.52,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$35.00

Average Price Target$28.57

Lowest Price Target$25.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Debanjana Chatterjee

JonesTrading

$26

Buy

310.74%

Upside

Reiterated

11/28/25

Buy Rating for Sagimet Biosciences: Promising Pipeline Developments and Strong Financial Position

Edward Nash

Canaccord Genuity

$28

Buy

342.34%

Upside

Reiterated

11/25/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sagimet Biosciences, Inc. Class A (NASDAQ: SGMT), Bristol-Myers Squibb (NYSE: BMY) and Palvella Therapeutics (NASDAQ: PVLA)We believe Sagimet's TVB-3567 offers a clinically de-risked option. We expect Phase I data from this program to read out in 1H26, which could then see the program move into Phase II development in 2H26.

Ritu Baral

TD Cowen

―

Buy

―

Reiterated

11/16/25

Sagimet Biosciences, Inc.: Promising Pipeline and Strong Financial Position Justify Buy RatingWe believe the full Ph3 program will cost ~$400M. Recall, the Ph3 program is made up of two Ph3 trials.

Jonathan Wolleben

Citizens JMP

$33→$35

Buy

452.92%

Upside

Reiterated

11/14/25

Sagimet Biosciences price target raised to $35 from $33 at Citizens JMPSagimet Biosciences price target raised to $35 from $33 at Citizens JMP

Jay Olson

Oppenheimer

$25

Buy

294.94%

Upside

Reiterated

11/14/25

Sagimet Biosciences, Inc. Class A (SGMT) Receives a Buy from Oppenheimer

Brandon Folkes

H.C. Wainwright

$29

Buy

358.14%

Upside

Reiterated

11/14/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Vor Biopharma (NASDAQ: VOR), Omeros (NASDAQ: OMER) and Sagimet Biosciences, Inc. Class A (NASDAQ: SGMT)

Yun Zhong

Wedbush

$28

Buy

342.34%

Upside

Reiterated

11/13/25

Optimistic Buy Rating for Sagimet Biosciences Driven by Promising Clinical Progress and Strong Financial Position

Kaveri Pohlman

Clear Street

$29

Buy

358.14%

Upside

Reiterated

10/26/25

Sagimet Biosciences, Inc. Class A (SGMT) Receives a Buy from Clear Street

Thomas Smith

Leerink Partners

$26

Buy

310.74%

Upside

Reiterated

08/18/25

Promising Clinical Developments and Strategic Positioning Make Sagimet Biosciences a Buy

Yasmeen Rahimi

Piper Sandler

$67

Buy

958.45%

Upside

Reiterated

06/17/25

Analysts Offer Insights on Healthcare Companies: Pfizer (NYSE: PFE) and Sagimet Biosciences, Inc. Class A (NASDAQ: SGMT)

Ed Arce

Westpark Capital

$32

Buy

405.53%

Upside

Reiterated

03/11/25

Promising Pipeline and Positive Trial Data Support Buy Rating for Sagimet Biosciences

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Debanjana Chatterjee

JonesTrading

$26

Buy

310.74%

Upside

Reiterated

11/28/25

Buy Rating for Sagimet Biosciences: Promising Pipeline Developments and Strong Financial Position

Edward Nash

Canaccord Genuity

$28

Buy

342.34%

Upside

Reiterated

11/25/25

Ritu Baral

TD Cowen

―

Buy

―

Reiterated

11/16/25

Sagimet Biosciences, Inc.: Promising Pipeline and Strong Financial Position Justify Buy RatingWe believe the full Ph3 program will cost ~$400M. Recall, the Ph3 program is made up of two Ph3 trials.

Jonathan Wolleben

Citizens JMP

$33→$35

Buy

452.92%

Upside

Reiterated

11/14/25

Sagimet Biosciences price target raised to $35 from $33 at Citizens JMPSagimet Biosciences price target raised to $35 from $33 at Citizens JMP

Jay Olson

Oppenheimer

$25

Buy

294.94%

Upside

Reiterated

11/14/25

Sagimet Biosciences, Inc. Class A (SGMT) Receives a Buy from Oppenheimer

Brandon Folkes

H.C. Wainwright

$29

Buy

358.14%

Upside

Reiterated

11/14/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Vor Biopharma (NASDAQ: VOR), Omeros (NASDAQ: OMER) and Sagimet Biosciences, Inc. Class A (NASDAQ: SGMT)

Yun Zhong

Wedbush

$28

Buy

342.34%

Upside

Reiterated

11/13/25

Optimistic Buy Rating for Sagimet Biosciences Driven by Promising Clinical Progress and Strong Financial Position

Kaveri Pohlman

Clear Street

$29

Buy

358.14%

Upside

Reiterated

10/26/25

Sagimet Biosciences, Inc. Class A (SGMT) Receives a Buy from Clear Street

Thomas Smith

Leerink Partners

$26

Buy

310.74%

Upside

Reiterated

08/18/25

Promising Clinical Developments and Strategic Positioning Make Sagimet Biosciences a Buy

Yasmeen Rahimi

Piper Sandler

$67

Buy

958.45%

Upside

Reiterated

06/17/25

Analysts Offer Insights on Healthcare Companies: Pfizer (NYSE: PFE) and Sagimet Biosciences, Inc. Class A (NASDAQ: SGMT)

Ed Arce

Westpark Capital

$32

Buy

405.53%

Upside

Reiterated

03/11/25

Promising Pipeline and Positive Trial Data Support Buy Rating for Sagimet Biosciences

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sagimet Biosciences, Inc. Class A

1 Month

xxx

Success Rate

4/10 ratings generated profit

Average Return

+11.00%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 40.00% of your transactions generating a profit, with an average return of +11.00% per trade.

3 Months

xxx

Success Rate

6/10 ratings generated profit

Average Return

+38.26%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +38.26% per trade.

1 Year

Debanjana ChatterjeeJonesTrading

Success Rate

5/7 ratings generated profit

Average Return

+37.13%

reiterated a buy rating 16 days ago

Copying Debanjana Chatterjee's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +37.13% per trade.

2 Years

xxx

Success Rate

9/10 ratings generated profit

Average Return

+52.64%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 90.00% of your transactions generating a profit, with an average return of +52.64% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SGMT Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SGMT has received 10 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. SGMT average Analyst price target in the past 3 months is 28.57.

Each month's total comprises the sum of three months' worth of ratings.

SGMT Financial Forecast

SGMT Earnings Forecast

Next quarter’s earnings estimate for SGMT is -$0.42 with a range of -$0.48 to -$0.40. The previous quarter’s EPS was -$0.40. SGMT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year SGMT has Performed in-line its overall industry.

SGMT Sales Forecast

Next quarter’s sales forecast for SGMT is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. SGMT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year SGMT has Performed in-line its overall industry.

SGMT Stock Forecast FAQ

What is SGMT’s average 12-month price target, according to analysts?

Based on analyst ratings, Sagimet Biosciences, Inc. Class A’s 12-month average price target is 28.57.

What is SGMT’s upside potential, based on the analysts’ average price target?

Sagimet Biosciences, Inc. Class A has 351.34% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is SGMT a Buy, Sell or Hold?

Sagimet Biosciences, Inc. Class A has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.

What is Sagimet Biosciences, Inc. Class A’s price target?

The average price target for Sagimet Biosciences, Inc. Class A is 28.57. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $35.00 ,the lowest forecast is $25.00. The average price target represents 351.34% Increase from the current price of $6.33.

What do analysts say about Sagimet Biosciences, Inc. Class A?

Sagimet Biosciences, Inc. Class A’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of SGMT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Sagimet Biosciences, Inc. Class A (SGMT) Stock Forecast & Price Target

SGMT Analyst Ratings

SGMT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Sagimet Biosciences, Inc. Class A

SGMT Analyst Recommendation Trends

SGMT Financial Forecast

SGMT Earnings Forecast

SGMT Sales Forecast

SGMT Stock Forecast FAQ

Detailed List of Analyst Forecasts